Natural killer cell activity in patients with invasive cervical carcinoma: importance of a longitudinal evaluation in follow-up.
OBJECTIVE
To analyze longitudinally the basal natural killer cell activity in patients with invasive cervical carcinoma, the natural cytotoxicity was related to the most important known prognostic factors, and evaluated with respect to the clinical outcome of cervical disease.


METHODS
Forty-six patients with histologically proven invasive cervical carcinoma treated and followed at the Institute of Gynecology and Obstetrics, Ancona University, Salesi Hospital, were consecutively recruited from 1989 to 1992 and included into the study. For immunologic investigation, natural killer cell activity and peripheral blood T-lymphocyte subsets were tested before primary treatment and during the follow-up period, every 6 months. Natural killer activity was determined by target cell retention of the fluorescent dye carboxyfluorescein diacetate; the K 562 cell line was used as target cells.


RESULTS
A significant inverse relationship was observed between natural killer activity and disease stage (p = 0.001); patients with stage IV disease had the lowest level of natural cytotoxicity. The reduction of natural cytotoxicity was not accompanied by any alteration of lymphocyte distribution. The longitudinal analysis showed an increase of natural killer activity after surgical removal of the tumor, persisting during the follow-up, but all the 9 patients who recurred showed, at the time of disease recurrence, a significant decrease of their natural cytotoxic potential.


CONCLUSIONS
Natural killer cell activity seems to be a functional index of immune status, significantly related to the stage and the clinical outcome of disease.
Garzetti
G G
GG
Institute of Obstetrics and Gynecology, Ancona University, Italy.
Ciavattini
A
A
Muzzioli
M
M
Goteri
G
G
Mannello
B
B
Romanini
C
C
Fabris
N
N
D000230:Adenocarcinoma / Q000276:immunology*; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular; D007694:Killer Cells, Natural / Q000473:pathology*; D008137:Longitudinal Studies; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D013601:T-Lymphocytes / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000276:immunology*